Research on Malignancies in AIDS and Acquired Immune Suppression (R21)
The summary for the Research on Malignancies in AIDS and Acquired Immune Suppression (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Research on Malignancies in AIDS and Acquired Immune Suppression (R21): Executive Summary The purpose of this initiative is to stimulate research that will improve our understanding of the biological basis of development and progression of cancer in the context of Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS) or acquired immune suppression not associated with HIV infection such as organ transplantation. The NCI and NIDCR seek to encourage novel approaches to discovery and preclinical development of novel therapeutic agents and biomarkers for early diagnosis and monitoring of disease progression. Molecular epidemiologic studies of the role of chronic latent viruses and their interaction with one another or with environmental factors in the context of acquired immune suppression or HIV infection leading to the development of tumors or lesions with oncogenic potential are also of interest.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -This FOA utilizes the Exploratory/Developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-04-157, which solicits applications under the NIH Research Project Grant (R01) mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations include: for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of Local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support -Applicants may submit more than one application, provided each application is scientifically distinct.
|Federal Grant Title:||Research on Malignancies in AIDS and Acquired Immune Suppression (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PA-06-338|
|Type of Funding:||Grant|
|CFDA Descriptions:||Oral Diseases and Disorders Research 93.393 Cancer Cause and Prevention Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Multiple Receipt Dates - See Link to Full Announce|
|Posted Date:||Apr 07, 2006|
|Creation Date:||Apr 07, 2006|
|Archive Date:||Oct 02, 2007|
|Total Program Funding:|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||93.396 -- Cancer Biology Research|
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) For profit organizations other than small businesses Special district governments Public and State controlled institutions of higher education Independent school districts Public housing authorities/Indian housing authorities State governments Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) County governments
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Faith-based or community-based organizations
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...